| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035199382 |
| P356 | DOI | 10.1007/S12032-009-9268-Y |
| P8608 | Fatcat ID | release_s3wkmse3ova4hfzkdv2odfv4mu |
| P698 | PubMed publication ID | 19633962 |
| P2093 | author name string | Nurullah Zengin | |
| Berna Oksüzoğlu | |||
| Hüseyin Abali | |||
| Nuriye Yildirim Ozdemir | |||
| Doğan Uncu | |||
| Burçin Budakoglu | |||
| Hatice Odabaşi | |||
| Tunç Güler | |||
| P2860 | cites work | Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 |
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin | Q33421327 | ||
| Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer | Q33428767 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research | Q34581504 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Gastric carcinoma | Q40542262 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gas | Q44578293 | ||
| A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer | Q44902236 | ||
| CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study | Q45714364 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. | Q54127938 | ||
| Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial | Q68075135 | ||
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| docetaxel | Q420436 | ||
| P304 | page(s) | 680-684 | |
| P577 | publication date | 2009-07-25 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma | |
| P478 | volume | 27 |
| Q33403949 | Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma |
| Q46057636 | Chemotherapy treatment patterns and neutropenia management in gastric cancer |
| Q87515768 | Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel |
| Q40347623 | Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer |
| Q33440431 | Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials |
| Q37644000 | Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. |
| Q36058744 | NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo |
| Q43249734 | Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication |
| Q36396339 | Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. |
| Q90654884 | The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial |
| Q33808720 | The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma |
Search more.